Home > Gastroenterology > ECCO 2022 > Short-Term and Long-Term Treatment Results > Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Presented By
Dr Marie Truyens, Ghent University Hospital, Belgium
Conference
ECCO 2022
Trial
Phase 2, Trp-IBD
5-hydroxytryptophan was not superior to placebo in reducing fatigue among participants with quiescent inflammatory bowel disease (IBD) in the phase 2 Trp-IBD trial. However, a reduction in fatigue was reported in both treatment groups, suggesting that supporting therapies and attention for fatigue may have improved symptoms in these patients. Fatigue is common among patients with IBD, with 72% of the patients with active disease and 47% of the patients in remission reporting this symptom, explained Dr Marie Truyens (Ghent University Hospital, Belgium) [1]. Since tryptophan has been associated with fatigue in IBD, a multicentre, double-blind, cross-over, randomised-controlled trial (NCT03574948) was conducted to assess the efficacy of 5-hydroxytryptophan supplementation in fatigued patients with inactive IBD. The participants were randomis...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on